Xencor Inc. (XNCR)
| Bid | 9.7 |
| Market Cap | 682.42M |
| Revenue (ttm) | 119.7M |
| Net Income (ttm) | -252M |
| EPS (ttm) | -3.58 |
| PE Ratio (ttm) | -2.71 |
| Forward PE | -6.2 |
| Analyst | Buy |
| Ask | 12.4 |
| Volume | 714,697 |
| Avg. Volume (20D) | 626,141 |
| Open | 10.59 |
| Previous Close | 10.64 |
| Day's Range | 9.65 - 10.59 |
| 52-Week Range | 9.65 - 27.24 |
| Beta | 0.74 |
About XNCR
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with r...
Analyst Forecast
According to 8 analyst ratings, the average rating for XNCR stock is "Buy." The 12-month stock price forecast is $34, which is an increase of 251.06% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · businesswire.com
Xencor Reports Fourth Quarter and Full Year 2024 Financial ResultsPASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re...
